Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trial
新型 CDK2/4/6 抑制剂 culmerciclib (TQB3616) 联合氟维司群治疗既往接受过治疗的 HR 阳性、HER2 阴性晚期乳腺癌：一项随机、双盲、3 期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02475-6
Yin, Yongmei; Zhang, Qingyuan; Sun, Tao; Hao, Chunfang; Wang, Zhihong; Yang, Jin; Wang, Yongsheng; Shi, Yanxia; Sun, Jing; Ouyang, Quchang; Su, Haichuan; Wu, Jinsheng; Gan, Lu; Han, Meng; Gao, Liming; Wang, Xiaojia; Zhao, Bing; Li, Hui; Zhao, Jiuda; Yang, Hongwei; Ning, Fangling; Tian, Fuguo; Zhang, Juliang; Sun, Hongmei; Niu, Zhaofeng; Zong, Hong; Zang, Aimin; Wang, Xinshuai; Qian, Xinyu; Wu, Shikai; Nie, Jianyun; He, Lijia; Cheng, Ying; Hao, Yanrong; Zhai, Yi; Li, Huiping; Wang, Jingfen; Wei, Shihong; Li, Man; Liu, Yunjiang; Guo, Hongqiang; Hu, Qun; Liu, Lina; Han, Xinghua; Luo, Ruizhen; Ni, Mingli; Tang, Xianjun; Zhai, Zhenhua; Ding, Meiqian; Wang, Haibo; Shen, Peng; Wang, Xian; Liu, Lian; Chen, Wenyan; Liu, Gang; Cai, Zhengwen; Jiang, Zefei
